Hormonal
Maintaining lower HbA1c levels (<7%) is associated with slower progression of biological aging, as measured by the deficit accumulation frailty index, over an 8-year period in adults with type 2 diabetes.
If you have type 2 diabetes, keeping your average blood sugar (HbA1c) below 7% is linked to slower biological aging and less physical decline over time compared to higher levels. Work with your doctor to achieve this target safely, as it appears to protect your long-term health.
Baseline and average HbA1c levels over time of <7%, as compared with ≥8%, were associated with less increase in FI scores over 8 years (both P ≤ 0.002).
Why this rating
Large randomized controlled trial (Look AHEAD) with 4,169 participants and 8-year follow-up, though this specific analysis is observational within the trial arms.
Source
An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial
Felicia Simpson et al. · Diabetes Care · 2022
DOI 10.2337/dc22-1728
More from this paper
- Achieving a weight loss of greater than 5% is independently associated with slower progression of the frailty index in adults with type 2 diabetes, regardless of HbA1c levels.Good
- Consistent use of metformin (≥50% of assessments) is independently associated with slower progression of the frailty index in adults with type 2 diabetes, after adjusting for HbA1c and weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →